Insightful analysis from Jared Hopkins and colleages. It is an open question whether patients will save a penny - in fact, the follow on implications for formulary placement of competitors make it unclear whether weighted average prices will go up or down for those who may not want to switch therapy, for example. Add to this the opaque nature of the proceedings and it’s hard to imagine a stranger approach. The only certainty is that this has added to uncertainty for investors in the space. Our #gcea and #heor tools can help #marketaccess teams make better decisions in a very uncertain environment.
After years of opposition from the pharmaceutical industry and lawsuits seeking to halt the law that led to the new negotiated prices, resistance paled and legal efforts failed. The talks settled into a sometimes testy back and forth: hundreds of pages of paperwork, offers and rejected counteroffers, then rounds of meetings in windowless rooms with strict rules on how many people could attend. Here's our deeper-dive-story on the negotiated Medicare drugs prices under the Inflation Reduction Act announced this week, by myself, Peter Loftus and Joe Walker. What do you think of this? Will it help make drugs more affordable for patients? Will it have unintended consequences for industry investments in developing drugs?